Analysis of probiotic’s impact on the clinical manifestations and severity of acute respiratory infections-Reference-Cited by-同舟云学术

Analysis of probiotic’s impact on the clinical manifestations and severity of acute respiratory infections

Published:2024-08-07 Issue:11 Volume: Page:163-172
ISSN:2658-5790
Container-title:Meditsinskiy sovet = Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Zakharova I. N.¹^ORCID,Koshechkin S. I.²^ORCID,Odintsova V. Е.²^ORCID,Romanov V. A.²^ORCID,Popenko A. S.²^ORCID,Pervishko O. V.³^ORCID,Larina V. G.³^ORCID,Fedotova M. M.⁴^ORCID,Prokopyeva V. D.⁴^ORCID,Shegai L. V.⁵,Mozzhukhina M. V.¹

Affiliation:

1. Russian Medical Academy of Continuous Professional Education

2. Nobias Technologies LLC

3. Kuban State Medical University

4. Siberian State University

5. Children’s City Hospital No. 2

Abstract

Introduction. Acute respiratory infections cover majority of pediatric outpatient visits and hospitalizations, especially during the cold and flu epidemic season.Aim. To evaluate the effect of Baс-Set Cold/Flu probiotic on the clinical manifestations and severity of acute respiratory infections (ARI) along with standard symptomatic therapy during periods of increased morbidity (November 2023 – March 2024).Materials and methods. This study was an open-label, observational, multicenter study. The number of subjects was 234: 111 volunteers in the first group (experimental) and 123 volunteers in the second group (control) aged from 2 to 10 years inclusive (mean age 5.79) with a diagnosis of ARI. Patients of the first group took Bac-Set Cold/Flu probiotic along with standard symptomatic therapy in comparison with control group which took a standard symptomatic therapy only. Statistical analysis was performed using the R programming language.Results and discussion. The use of probiotic significantly reduced the number of complications and the prescription of antibiotic therapy by more than three times (5% in the probiotic group versus 17% in the control group). A significant difference was revealed in the total duration of the disease (the maximum period from the first symptom of fever to the fact of complete recovery, – absence of fever within last 48 hours) between groups (Mann- Whitney test, p-value = 0.017). In the experimental group, the average duration of illness was 6.2 ± 3.7 days, in the control group – 7.2 ± 3.1 days. A statistically significant difference in the duration of fever was also revealed (Mann-Whitney test, p-value = 0.006). In the control group, on average, fever lasted 1 day longer. The median maximum temperature in the probiotic group was 0.5 degrees lower at the 2nd visit compared to the control group. The use of the probiotic did not affect the symptoms of cough, nasal congestion and the color of nasal discharge, but a trend was recorded for the effect on the symptoms of sore throat.Conclusion. The use of a probiotic reduced the number of complications and the prescription of antibiotic therapy by more than three times, the duration of the disease and fever.

Publisher

Remedium, Ltd.

Reference14 articles.

1. Zakharova IN, Berezhnaya IV, Klimov LY, Kasyanova AN, Dedikova OV, Koltsov KA. Probiotics in the management of respiratory diseases: ways of interaction and therapeutic perspectives. Meditsinskiy Sovet. 2019;(2):173–182. (In Russ.) https://doi.org/10.21518/2079701X-2019-2-173-182.

2. Rueda ZV, Aguilar Y, Maya MA, López L, Restrepo A, Garcés C et al. Etiology and the challenge of diagnostic testing of community-acquired pneumonia in children and adolescents. BMC Pediatr. 2022;31;22(1):169. https://doi.org/10.1186/s12887-022-03235-z.

3. Wahab S, Almaghaslah D, Mahmood SE, Ahmad MF, Alsayegh AA, Abu Haddash YM et al. Pharmacological Efficacy of Probiotics in Respiratory Viral Infections: A Comprehensive Review. J Pers Med. 2022;12(8):1292. https://doi.org/10.3390/jpm12081292.

4. Shahbazi R, Yasavoli-Sharahi H, Alsadi N, Ismail N, Matar C. Probiotics in Treatment of Viral Respiratory Infections and Neuroinflammatory Disorders. Molecules. 2020;25(21):4891. https://doi.org/10.3390/molecules25214891.

5. Zhao Y, Dong BR, Hao Q. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2022;8(8):CD006895. https://doi.org/10.1002/14651858.CD006895.pub4.